Fulltext present in this item

Thumbnail
Fulltext: 127295.pdf
Format: PDF
Description: publisher's version
Embargo: until further notice
Title: Doxorubicin/cyclophosphamide with concurrent versus sequential docetaxel as neoadjuvant treatment in patients with breast cancer.
Author(s): Vriens, B.E.; Aarts, M.J.; Vries, B. de; Gastel, S.M. van; Wals, J.; Smilde, T.J. ; Warmerdam, L.J. van; Boer, M. de ; Spronsen, D.J. van ; Borm, G.F. ; Tjan-Heijnen, V.C. ; Stienen, J.J.C.; Hermens, R.P.M.G. ; Wennekes, L. ; Schans, S.A. van de; Dekker, H.M. ; Blijlevens, N.M.A. ; Maazen, R.W.M. van der ; Adang, E.M.M. ; Krieken, J.H.J.M. van ; Ottevanger, P.B. ; et al.
Publication year: 2013
Source: European Journal of Cancer, vol. 49, iss. 15, (2013), pp. 3102-3110
ISSN: 0959-8049
DOI: https://doi.org/10.1016/j.ejca.2013.06.012
Publication type: Article / Letter to editor

Please use this identifier to cite or link to this item : https://hdl.handle.net/2066/127295   https://hdl.handle.net/2066/127295

Display more details
Subject: N4i 2: Invasive mycoses and compromised host ONCOL 3: Translational research
NCEBP 2:Evaluation of complex medical interventions ONCOL 4:Quality of Care
NCEBP 4: Quality of hospital and integrated care
NCEBP 4: Quality of hospital and integrated care ONCOL 4: Quality of Care
NCEBP 6: Quality of nursing and allied health care
NCEBP 7: Effective primary care and public health
ONCOL 3: Translational research NCMLS 3: Tissue engineering and pathology
ONCOL 4: Quality of Care NCEBP 4: Quality of hospital and integrated care
ONCOL 5: Aetiology, screening and detection
NCEBP 6: Quality of nursing and allied health care
ONCOL 3: Translational research NCMLS 3: Tissue engineering and pathology
Tijdelijke code tbv inlezen publicaties Radboudumc - Alleen voor gebruik door Radboudumc
Organization: Internal Medicine
Medical Oncology
IQ Healthcare
Radiology
Haematology
Radiation Oncology
Primary and Community Care
Health Evidence
Pathology
Journal title:
European Journal of Cancer
Volume: vol. 49
Issue: iss. 15
Page start: p. 3102
Page end: p. 3110
Abstract:
Abstract BACKGROUND: This study was designed to determine whether delivering neo-adjuvant chemotherapy at a higher dose in a shorter period of time improves outcome of breast cancer patients. PATIENTS AND METHODS: Women with newly diagnosed breast cancer were randomly assigned to neoadjuvant chemotherapy of four cycles of doxorubicin and cyclophosphamide followed by four cycles of docetaxel (AC 60/600 - T 100mg/m(2)) or six cycles of TAC (75/50/500mg/m(2)) every 3 weeks. The primary endpoint was the pathologic complete response (pCR) rate, defined as no invasive tumour present in the breast. RESULTS: In total, 201 patients were included. Baseline characteristics were well balanced. AC-T resulted in pCR in 21% and TAC in 16% of patients (odds ratio 1.44 (95% confidence interval (CI) 0.67-3.10). AC-T without primary granulocyte-colony stimulating factor (G-CSF) prophylaxis was associated with more febrile neutropenia compared to TAC with primary G-CSF prophylaxis (23% versus 9%), and with more grade 3/4 sensory neuropathy (5% versus 0%). CONCLUSIONS: With a higher cumulative dose for the concurrent arm, no differences were observed between the two treatment arms with respect to pCR rate. The differential toxicity profile could partly be explained by different use of primary G-CSF prophylaxis. Copyright © 2013 Elsevier Ltd. All rights reserved. KEYWORDS: Breast cancer, Cyclophosphamide, Docetaxel, Doxorubicin, Neoadjuvant chemotherapy

This item appears in the following Collection(s)

Browse

Statistics